Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) was the target of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 8,590,000 shares, a growth of 84.7% from the June 30th total of 4,650,000 shares. Based on an average daily volume of 27,920,000 shares, the days-to-cover ratio is presently 0.3 days.
Allena Pharmaceuticals Price Performance
NASDAQ:ALNA opened at $0.11 on Friday. The company has a 50 day simple moving average of $0.14 and a two-hundred day simple moving average of $0.26. Allena Pharmaceuticals has a fifty-two week low of $0.07 and a fifty-two week high of $1.17.
Get Allena Pharmaceuticals alerts:Allena Pharmaceuticals (NASDAQ:ALNA – Get Rating) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.07. As a group, equities research analysts anticipate that Allena Pharmaceuticals will post -0.31 earnings per share for the current year.
Institutional Trading of Allena Pharmaceuticals
A hedge fund recently raised its stake in Allena Pharmaceuticals stock. Kestra Advisory Services LLC increased its position in Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) by 53.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 161,500 shares of the company's stock after purchasing an additional 56,500 shares during the period. Kestra Advisory Services LLC owned approximately 0.20% of Allena Pharmaceuticals worth $96,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.52% of the company's stock.About Allena Pharmaceuticals
(Get Rating)
Allena Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.
Further Reading
- Get a free copy of the StockNews.com research report on Allena Pharmaceuticals (ALNA)
- Procter's Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.